Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Cytochrome P450 2C8 Inhibitors [MoA]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
Drug Reports Deaths Death Rate Hosp. Life-Threat. Avg Age % Female
CLOPIDOGREL BISULFATE 46,012 5,327 11.6% 24,774 3,750 70.0 yrs 41.2%
ABIRATERONE 34,511 7,180 20.8% 8,816 757 74.9 yrs 0.5%
NILOTINIB 23,171 4,543 19.6% 4,846 683 56.5 yrs 47.7%
PAZOPANIB 21,208 5,612 26.5% 4,347 572 61.2 yrs 41.2%
CANNABIDIOL 18,243 1,563 8.6% 5,149 104 21.6 yrs 45.2%
DEFERASIROX 11,322 2,661 23.5% 4,008 357 49.8 yrs 50.1%
TUCATINIB 6,042 640 10.6% 1,717 65 57.6 yrs 95.5%
ATAZANAVIR 5,434 425 7.8% 1,112 118 42.7 yrs 43.0%
PERAMPANEL 4,446 249 5.6% 1,760 310 34.5 yrs 52.6%
RIPRETINIB 4,432 465 10.5% 948 16 66.8 yrs 45.3%

Head-to-Head Comparisons

CLOPIDOGREL BISULFATE vs ABIRATERONE CLOPIDOGREL BISULFATE vs NILOTINIB CLOPIDOGREL BISULFATE vs PAZOPANIB CLOPIDOGREL BISULFATE vs CANNABIDIOL ABIRATERONE vs NILOTINIB ABIRATERONE vs PAZOPANIB ABIRATERONE vs CANNABIDIOL NILOTINIB vs PAZOPANIB NILOTINIB vs CANNABIDIOL PAZOPANIB vs CANNABIDIOL
← Back to Cytochrome P450 2C8 Inhibitors [MoA] Class side effects →